Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis Infection

AUTOR(ES)

Zhang, Tianyu

FONTE

American Thoracic Society

RESUMO

Rationale: Regimens recommended to treat latent tuberculosis infection (LTBI) are 3 to 9 months long. A 2-month rifampin+pyrazinamide regimen is no longer recommended. Shorter regimens are highly desirable. Because substituting rifapentine for rifampin in the standard regimen for active tuberculosis halves the treatment duration needed to prevent relapse in mice, we hypothesized daily rifapentine-based regimens could shorten LTBI treatment to 2 months or less.

Documentos Relacionados

• Short-course isoniazid plus rifapentine therapy for latent tuberculosis in Brazil
• Efficacy of Short-Course Ceftriaxone Therapy for Borrelia burgdorferi Infection in C3H Mice
• Urology—Important Advances in Clinical Medicine: Short-Course Chemotherapy for Genitourinary Tuberculosis
• Osteonecrosis of the femoral head in men following short-course corticosteroid therapy: a report of 15 cases
• Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis.